Bebtelovimab potently neutralizes all SARS-CoV-2 variants of concern

By | April 27, 2022
The current study, escribes a new mAb LY-CoV1404 (bebtelovimab) from Eli Lilly, with high neutralization potency with a broad spectrum of activity across all current variants.